
BiotechTV - News
ASGCT 2025: Capsida Biotherapeutics is using its expertise in capsid design to develop gene therapies that are tissue specific, and in the case of the CNS, can be delivered via IV and crosses the BBB
10 min•14 maj 2025
Om avsnittet
CEO Peter Anastasiou describes the importance of capsid design and how Caspida is developing its own gene therapies for CNS conditions. A first program recently had its IND cleared.
Fler avsnitt
Visa alla avsnitt av BiotechTV - NewsBiotechTV - News med BiotechTV finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.